Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Invested Capital (2019 - 2025)

Allogene Therapeutics' Invested Capital history spans 7 years, with the latest figure at $315.3 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 32.0% year-over-year to $315.3 million; the TTM value through Sep 2025 reached $315.3 million, down 32.0%, while the annual FY2024 figure was $422.2 million, 17.58% down from the prior year.
  • Invested Capital for Q3 2025 was $315.3 million at Allogene Therapeutics, down from $344.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.1 billion in Q1 2021 and bottomed at $315.3 million in Q3 2025.
  • The 5-year median for Invested Capital is $592.0 million (2023), against an average of $645.8 million.
  • The largest annual shift saw Invested Capital soared 76.38% in 2021 before it crashed 33.1% in 2025.
  • A 5-year view of Invested Capital shows it stood at $925.2 million in 2021, then decreased by 27.92% to $666.9 million in 2022, then decreased by 23.19% to $512.2 million in 2023, then decreased by 17.58% to $422.2 million in 2024, then fell by 25.31% to $315.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Invested Capital are $315.3 million (Q3 2025), $344.6 million (Q2 2025), and $385.4 million (Q1 2025).